Serum-Free hPSC Differentiation into Consistent MSCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current differentiation protocols for human pluripotent stem cells (hPSCs) into multipotent mesenchymal stromal cells (MSCs) rely on undefined reagents like fetal bovine serum (FBS) and trypsin, which are not clinically compliant and result in variable, heterogenous, and limited expansion capacities.
Innovation Solution
A serum-free method involving Dulbecco's Modified Eagle Medium (DMEM), KnockOut™ Serum Replacement (KOSR), and GlutaMAX, with optional Fibroblast Growth Factor 2 (FGF-2), is used to differentiate pluripotent stem cells into MSCs, utilizing ReLeSR or TrypLE for dissociation and culturing on gelatin-coated plates to maintain cell viability and multipotency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fetal bovine serum (FBS) and trypsin are used for differentiation, then cell differentiation can be achieved, but clinical compliance is compromised and batch variability increases
Solution Approach 1:
The patent changes the chemical composition parameters of the culture medium by replacing FBS with defined serum-free supplements and modifying the differentiation protocol to use specific growth factors (bFGF, TGF-beta1, dexamethasone, L-ascorbic acid) at controlled concentrations and durations, achieving both clinical compliance and manufacturing consistency
Solution Approach 2:
The patent extracts and eliminates FBS from the differentiation protocol, removing the source of batch variability and animal-derived contaminants, while replacing it with chemically defined alternatives that provide consistent results and meet clinical standards
2Productivity
If primary human MSCs are isolated from tissues, then MSCs can be obtained, but expansion capacity is limited to approximately 20 passages
Solution Approach 1:
The patent performs preliminary differentiation of hPSCs into MSCs under controlled serum-free conditions before clinical application, creating a consistent cell population with defined characteristics that can be expanded reliably without the passage limitations of primary tissue-isolated MSCs
Solution Approach 2:
The patent changes the culture conditions by using serum-free media with specific growth factor combinations, which alters the cellular behavior to enable unlimited expansion while maintaining consistent MSC characteristics and avoiding the heterogeneity of primary MSCs
3Manufacturing precision
If undefined reagents like FBS are used, then cell culture can be maintained, but manufacturing precision and batch consistency deteriorate
Solution Approach 1:
The patent precisely defines the chemical composition parameters of the culture medium by specifying exact concentrations of growth factors (bFGF: 10-100 ng/mL, TGF-beta1: 10-100 pg/mL), vitamins, and trace elements, eliminating the undefined variables present in FBS-based protocols and achieving reproducible batch-to-batch results
Data Source
AI summary
The present invention relates generally to the field of stem cell differentiation. In particular, the invention relates to a serum-free method for differentiating stem cells into multipotent mesenchymal stromal cells (MSCs). The invention also relates to serum-free media for cell culture. In an aspect of the present invention, there is provided a serum-free composition for differentiating pluripotent stem cells into multipotent MSCs, the composition comprising Dulbecco's Modified Eagle Medium (DMEM), KnockOut™ Serum Replacement (KOSR) and GlutaMAX.